Multidrug-resistant and extensively drug-resistant tuberculosis (TB) killed millions of people every year. BPaL and Nitroimidazole drugs Pretomanid, Delamanid’s approving brings hope for our ending TB in the future.

Sotorasib (AMG 510) target undruggable target KRAS, X-crystal structure of AMG510 in complex with KRASG12C was reported, also the synthesis of AMG and MRTX849 was summarized.

Absolutely, Sotorasib (AMG 510) and MRTX849 are the first line KRAS inhibitors, kinds of company are following the target as well, we summarized the patent disclosed recently, maybe helpful you!

From the origin of medicine and composition of medicine to learn what is pharmaceutical intermediate, and what important rule it plays on the development of new drugs.

TNG462 has the potential for broader and deeper clinical activity in MTAP-deleted solid tumors than the MTA-cooperative PRMT5 currently being evaluated in clinical trials.

STC-15 is a first-in-class an oral small molecule inhibitor of RNA modification and is the first ever RNA methyltransferase inhibitor. Subjects With Advanced Malignancies (NCT05584111) is recruiting

CHK-336 is a first-in-class, liver-targeted, oral small molecule LDHA inhibitor being developed for the treatment of primary and idiopathic hyperoxaluria.

STX-478 is designed to improve outcomes in patients harboring prevalent PI3Kα mutations in their tumors and has shown activity in both kinase and helical domain mutated tumors in preclinical models.

JNT-517, oral small molecule inhibitor of Solute Carrier Family 6 Member 19 (SLC6A19)